Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Switch Maintenance Pembrolizumab in Patients With Non Small Cell Lung Cancer (NSCLC) Who do Not Progress After First Line Platinum Doublet Chemotherapy. (SWIPE)

NCT02705820 is registered in ClinicalTrials.gov with Bank of Cyprus Oncology Centre as lead sponsor.

NCT NCT02705820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02705820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Switch Maintenance Pembrolizumab in Patients With Non Small Cell Lung Cancer (NSCLC) Who do Not Progress After First Line Platinum Doublet Chemotherapy. (SWIPE)
Lead sponsor
Bank of Cyprus Oncology Centre
Phase
Phase 2
Overall status
Completed
Start date
April 25, 2016
Completion date
May 2, 2023
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non small cell lung cancer